Section 7.01 Regulation FD Disclosure.
upon November 21, 2022, SAB Biotherapeutics, Inc. (“Company” or “SAB”) has made available its latest corporate strategy presentation (“Presentation”) in the Investor Relations section of its website. A copy of the presentation is provided as Exhibit 99.1 and is incorporated herein by reference.
The foregoing (including Exhibit 99.1) has been filed pursuant to Section 7.01 and shall not be deemed to have been filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”), or otherwise subject to is not considered. Nor will it be deemed incorporated by reference into any filings under the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act.The information contained in the presentation is summary information and we Securities and Exchange Commission
(“SEC”) and other public notices we may make from time to time by press release or otherwise.
Cautionary Note Regarding Forward-Looking Statements Certain statements made in this document that are not historical facts are forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.believe, “could”, “will”, “estimate”, “continue”, “predict”, “intend”, “expect”, “should”, “would”, “plan”, “predict”, “likely”, “believe”, “seek”, “future”, “prospect” and similar expressions that predict or indicate future events or trends, or history These forward-looking statements include information about our influenza program, the C. diff. program, type 1 diabetes program, and other discovery programs; , the results, including the timing of development SAB-176, SAB-185 and SAB-195 (including IND filings or proposed clinical trials), financial projections, future financial and operational results (including estimated cost savings and cash runways), potential future government and other third-party collaborations or funding with the results of the offered program (including negotiations) Department of Defense).
These statements are based on current expectations of SAB They are not projections of actual performance and are not intended to serve as guarantees, projections, definitive statements or guarantees of facts or probabilities and should not be relied upon by investors. These statements are only current expectations or expectations and are subject to known and unknown risks, uncertainties and other factors that may be beyond our control. It is difficult or impossible to predict actual events or circumstances and these risks and uncertainties make it difficult to predict the results, performance or achievements of our company or our industry in these forward-looking statements. may be significantly different from the original. For more information on risks and uncertainties, see the section entitled “Risk Factors” in the most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings. please. SEC, available at https://www.sec.gov/. Except as otherwise provided by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they are made, as a result of new information, future events, circumstances or otherwise.
Item 8.01 Other Events.
As previously disclosed, October 5, 2022we have received written notice Nasdaq Stock Market LLC (“Nasdaq”) has informed us that the closing bid price for our common stock was below 5450(a)(1) and therefore has not complied with Nasdaq Listing Rules 5450(a)(1) . $1.00 Per share requirement for 30 consecutive business days prior to written notice.
upon November 21, 2022the Company will receive written notice from Nasdaq that Nasdaq will, for 10 consecutive business days, November 7, 2022 To November 18, 2022the minimum closing price of our common stock is at least $1.00 per share. Accordingly, Nasdaq has determined that the Company has reinstated compliance with Listing Rule 5450(a)(1), indicating that this matter has now been resolved.
Item 9.01 Financial Statements and Materials.
Exhibit Number Description
99.1 Presentation dated November 21, 2022
104 Cover Page Interactive Data File-the cover page XBRL tags are
embedded within the Inline XBRL document.
————————————————– ——————————
© Edgar Online, Source glance
